
    
      This is an open-label, single arm, study of sapacitabine administered in alternating cycles
      with decitabine in elderly patients with previously untreated AML (Part 1) or concomitantly
      with venetoclax in adult patients with relapsed or refractory AML or MDS (Part 2). Treatment
      will be administered on an outpatient basis. One treatment cycle is 4 weeks.
    
  